KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2025)

Historic Receivables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $1.5 billion.

  • Amneal Pharmaceuticals' Receivables rose 2027.06% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 2027.06%. This contributed to the annual value of $1.3 billion for FY2024, which is 851.48% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Receivables stood at $1.5 billion for Q3 2025, which was up 2027.06% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Receivables registered a high of $1.5 billion during Q3 2025, and its lowest value of $585.5 million during Q1 2022.
  • Its 5-year average for Receivables is $1.2 billion, with a median of $1.2 billion in 2022.
  • Its Receivables has fluctuated over the past 5 years, first surged by 10603.71% in 2021, then crashed by 4544.35% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Receivables stood at $1.2 billion in 2021, then rose by 15.52% to $1.4 billion in 2022, then fell by 12.2% to $1.2 billion in 2023, then grew by 8.51% to $1.3 billion in 2024, then grew by 11.87% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.3 billion during Q1 2025.